Simple Summary In our journey to fight cancer, biomarkers for prediction and efficacy of therapies could help medical practitioners to give patients the best available treatments in a timely fashion. Non-coding RNA, in most recent times, has been shown to play crucial roles for cancer growth. An exponential increase of evidence in the clinical literature supports their implication to predict patients' outcomes. In this article, we summarize the current predictive and prognostic value of non-coding RNA in breast cancer. For decades since the central dogma, cancer biology research has been focusing on the involvement of genes encoding proteins. It has been not until more recent times that a new molecular class has been discovered, named non-coding RNA (ncRNA), which has been shown to play crucial roles in shaping the activity of cells. An extraordinary number of studies has shown that ncRNAs represent an extensive and prevalent group of RNAs, including both oncogenic or tumor suppressive molecules. Henceforth, various clinical trials involving ncRNAs as extraordinary biomarkers or therapies have started to emerge. In this review, we will focus on the prognostic and diagnostic role of ncRNAs for breast cancer.
